Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 31, 2025 (11 months ago)

Globe Clotrimazole Cream

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Globe Clotrimazole Cream, USP, 1 %, Net Wt. 1 oz (28.4g), Distributed by: Trifecta Pharmaceuticals USA, 101 NE Third Avenue, Suite 1500, Ft. Lauderdale, FL 33301 USA, Made in India, NDC 69396-087-01.

Affected NDC 69396-0087-01

Compare with the code on your package — it is the most precise check available.

Drug: Clotrimazole

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Clotrimazole
NDC 69396-0087
1 g/100g Cream
Topical
Trifecta Pharmaceuticals USA LLC OTC
Recalling firm
Blossom Pharmaceuticals
NDC code
69396-087-01
Origin
India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0210-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Clotrimazole recalls

See all
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0638-2026
Class II · Moderate risk

Cura Hongos

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0634-2026
Class II · Moderate risk

Lucky Super Soft

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0629-2026
Class II · Moderate risk

Cura Hongos

CGMP Deviations

Terminated cGMP deviation Kenil Healthcare Private Limited D-0423-2025

Other recalls by Blossom Pharmaceuticals

All 2025 recalls
Class II · Moderate risk

Nivagen

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 75834-170-02 D-0209-2026